Cargando…
A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1
BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by the loss of dystrophin, which results in inflammation, fibrosis, and the inhibition of myoblast differentiation in skeletal muscle. Catalpol, an iridoid glycoside, improves skeletal muscle function by enhancing m...
Autores principales: | Xu, Dengqiu, Zhao, Lei, Jiang, Jingwei, Li, Sijia, Sun, Zeren, Huang, Xiaofei, Li, Chunjie, Wang, Tao, Sun, Lixin, Li, Xihua, Jiang, Zhenzhou, Zhang, Luyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567147/ https://www.ncbi.nlm.nih.gov/pubmed/32869445 http://dx.doi.org/10.1002/jcsm.12581 |
Ejemplares similares
-
TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy
por: Xu, Dengqiu, et al.
Publicado: (2020) -
Circulating Muscle-specific miRNAs in Duchenne Muscular Dystrophy Patients
por: Li, Xihua, et al.
Publicado: (2014) -
Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012) -
Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021) -
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
por: Sun, Chengmei, et al.
Publicado: (2020)